In Europe, hydroquinone is a forbidden cosmetic ingredient. It is, however, still abundantly used because of its effective skin-whitening properties. The question arises as to whether the quantities of hydroquinone used become systemically available and may cause damage to human health. Dermal absorption studies can provide this information. In the EU, dermal absorption has to be assessed in vitro since the Cosmetic Regulation 1223/2009/EC forbids the use of animals. To obtain human-relevant data, a Franz diffusion cell protocol was validated using human skin. The results obtained were comparable to those from a multicentre validation study. The protocol was applied to hydroquinone and the dermal absorption ranged between 31 and 44%, which is within the range of published in vivo human values. This shows that a well-validated in vitro dermal absorption study using human skin provides relevant human data. The validated protocol was used to determine the dermal absorption of illegal skin-whitening cosmetics containing hydroquinone. All samples gave high dermal absorption values, rendering them all unsafe for human health. These results add to our knowledge of illegal cosmetics on the EU market, namely that they exhibit a negative toxicological profile and are likely to induce health problems.

Keywords:
Percutaneous absorption, Cosmetic products, Franz diffusion cell, Bleaching agents, Human skin
1.
Parvez S, Kang M, Chung H-S, Cho C, Hong M-C, Shin M-K, et al: Survey and mechanism of skin depigmenting and lightening agents. Phytother Res 2006;20:921-934.
2.
Nordlund JJ, Grimes PE, Ortonne JP: The safety of hydroquinone. J Eur Acad Dermatol Venereol 2006;20:781-787.
3.
Gupta AK, Gover MD, Nouri K, Taylor S: The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006;55:1048-1065.
4.
Ladizinski B, Mistry N, Kundu RV: Widespread use of toxic skin lightening compounds: medical and psychosocial aspects. Dermatol Clin 2011;29:111-123.
5.
Denton CR, Lerner AB, Fitzpatrick TB: Inhibition of melanin formation by chemical agents. J Invest Dermatol 1952;18:119-135.
6.
Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa D: A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol 2003;42:153-156.
7.
Levitt J: The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol 2007;57:854-872.
8.
Kooyers TJ, Westerhof W: Toxicology and health risks of hydroquinone in skin lightening formulations. J Eur Acad Dermatol Venereol 2006;20:777-780.
9.
Desmedt B, Courselle P, De Beer JO, Rogiers V, Deconinck E, De Paepe K: Illegal cosmetics on the EU market: a threat for human health? Arch Toxicol 2014;88:1765-1766.
10.
Desmedt B, Van Hoeck E, Rogiers V, Courselle P, De Beer JO, De Paepe K, et al: Characterization of suspected illegal skin whitening cosmetics. J Pharm Biomed Anal 2014;90:85-91.
11.
EU Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Official J Eur Union 2009;L342:59. http://ec.europa.eu/health//sites/health/files/scientific_committees/consumer_safety/docs/sccs_s_002.pdf (accessed March 2015).
12.
European Commission: SCCS 2010: SCCS/1358/10, basic criteria for the in vitro assessment of dermal absorption of cosmetic ingredients, adopted during the 7th plenary meeting (2010). http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_DOI:10.2772/25843.
13.
OECD/OCDE: OECD guideline for the testing of chemicals: skin absorption: in vitro method, 428, adopted April 2004. https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg428-508.pdf.
14.
van de Sandt JJM, van Burgsteden JA, Cage S, Carmichael PL, Dick I, Kenyon S, et al: In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul Toxicol Pharmacol 2004;39:271-281.
15.
Desmedt B, Courselle P, De Beer JO, Rogiers V, Deconinck E, De Paepe K: In vitro dermal absorption: sample application and seal quality in a Franz diffusion cell system. Skin Pharmacol Physiol 2015;28:245-249.
16.
Panel on Plant Protection Products and their Residues: Guidance on dermal absorption. EFSA J 2012;10:2655.
17.
Schallreuter KU, Rokos H, Chavan B, Gillbro JM, Cemeli E, Zothner C, et al: Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes, and melanoma cells. Free Radic Biol Med 2008;44:538-546.
18.
Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, et al: Final amended safety assessment of hydroquinone as used in cosmetics. Int J Toxicol 2014;29:274S-287S.
19.
Baert B, Vansteelandt S, De Spiegeleer B: Ion mobility spectrometry as a high-throughput technique for in vitro transdermal Franz diffusion cell experiments of ibuprofen. J Pharm Biomed Anal 2011;55:472-478.
20.
Barber ED, Hill T, Schum DB: The percutaneous absorption of hydroquinone (HQ) through rat and human skin in vitro. Toxicol Lett 1995;80:167-172.
21.
Rougier A, Lotte C, Maibach HI: In vivo relationship between percutaneous absorption and transepidermal water loss; in Bronaugh R, Maibach HI (eds): Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methodology. New York, CRC Press 2005, pp 95-106.
22.
Gomaa YA, Morrow DIJ, Garland MJ, Donnelly RF, El-Khordagui LK, Meidan VM: Effects of microneedle length, density, insertion time and multiple applications on human skin barrier function: assessments by transepidermal water loss. Toxicol Vitr 2010;24:1971-1978.
23.
Larsen RH, Nielsen F, Sørensen JA, Nielsen JB: Dermal penetration of fentanyl: inter- and intraindividual variations. Pharmacol Toxicol 2003;93:244-248.
24.
Wester RC, Melendres J, Hui X, Cox R, Serranzana S, Zhai H, et al: Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. J Toxicol Environ Health A 1998;54:301-317.
25.
US Food and Drug Administration Department of Health and Human Services: Nomination profile: hydroquinone [CAS 123-31-9]. Supporting information for the toxicological evaluation by the National Toxicology Program. 21 May 2009. https://ntp.niehs.nih.gov/ntp/noms/support_docs/hydroquinone_may2009.pdf.
26.
European Commission: The SCCS notes of guidance for the testing of cosmetic substances and their safety evaluation. SCCS/1501/12. 2012. http://ec.europa.eu/health/scientific_committees/consumer_safety.
27.
OECD SIDS: Hydrquinone: Cas No: 123-31-9. Assessment profile 2002, pp 1-109. http://webnet.oecd.org/hpv/UI/handler.axd?id=7ca97271-99ed-4918-90e0-5c89d1ce200c.
28.
Wester RC, Maibach HI: Regional variation in percutaneous absorption: principles and applications to human risk assessment; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methodology, ed 4. London, Taylor and Francis, 2005, pp 85-93.
29.
SCCNFP: Opinion of the Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumers concerning the use of benzoyl peroxide (BPO), hydroquinone (HQ), hydroquinone methylether (MEHQ) in artificial nail systems. SCCNFP/0486/01. http://ec.europa.eu/health/archive/ph_risk/committees/sccp/documents/out167_en.pdf.
30.
Cosmetic Ingredient Review: About the Cosmetic Ingredient Review. http://www.cir-safety.org/about (accessed July 2014).
31.
Frasch HF, Dotson GS, Bunge AL, Chen CP, Cherrie JW, Kasting GB, et al: Analysis of finite dose dermal absorption data: implications for dermal exposure assessment. J Expo Sci Environ Epidemiol 2013;24:65-73.
32.
Olumide YM, Akinkugbe AO, Altraide D, Mohammed T, Ahamefule N, Ayanlowo S, et al: Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008;47:344-353.
33.
Katsambas AD, Stratigos AJ: Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol 1961;19:483-488.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.